Shionogi & Co logo

4507 - Shionogi & Co News Story

¥6043 -33.0  -0.5%

Last Trade - 07/08/20

Sector
Healthcare
Size
Large Cap
Market Cap £13.23bn
Enterprise Value £10.73bn
Revenue £2.25bn
Position in Universe 67th / 3862

BRIEF-FDA Accepts Shionogi's Supplemental New Drug Application With Priority Review For Fetroja

Mon 1st June, 2020 1:30pm
June 1 (Reuters) - Shionogi & Co Ltd  4507.T :
    * FDA ACCEPTS SHIONOGI’S SUPPLEMENTAL NEW DRUG APPLICATION
WITH
PRIORITY REVIEW FOR FETROJA® (CEFIDEROCOL) FOR THE TREATMENT OF
HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED
BACTERIAL PNEUMONIA
    * SHIONOGI & CO LTD -U.S. FDA ACCEPTED CO'S SNDA FOR FETROJA
&
GRANTED PRIORITY REVIEW DESIGNATION WITH PDUFA DATE OF SEPTEMBER
27, 2020

Source text for Eikon:  ID:nBwbQWlfca 
Further company coverage:  4507.T 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.